GE HealthCare Technologies (GEHC) Financials

GE HealthCare’s latest results show improving operating momentum, although cash conversion and leverage remain important investor watchpoints. In Q2 2026, revenue increased to $5.30 billion from $5.01 billion in Q2 2025, a 5.7% gain. Gross profit rose 9.8% to $2.18 billion, while operating income climbed 13.0% to $739 million. This lifted the operating margin to approximately 14.0%, compared with 13.1% a year earlier.

Profitability also improved meaningfully in the latest quarter. Net income attributable to common shareholders rose 15.4% year over year to $561 million, and diluted earnings per share increased to $1.24 from $1.06. The improvement follows a weaker Q1 2026, when operating income and common net income declined from the restated Q1 2025 figures, suggesting that quarterly results can be volatile.

GE HealthCare’s balance sheet has expanded since 2023, partly reflecting acquisitions. Total assets reached $37.25 billion in Q2 2026, up from $32.45 billion at the end of 2023. However, goodwill totaled $15.10 billion, or roughly 41% of assets, increasing the importance of future acquisition performance and impairment risk.

Cash flow was positive but modest relative to earnings. Q2 2026 operating cash flow was $168 million, compared with $94 million in Q2 2025, while capital spending was $100 million, producing approximately $68 million of free cash flow. Working-capital changes reduced operating cash flow by $468 million, highlighting continued pressure from receivables, inventory and other operating assets.

• Revenue growth is holding up: Q2 2026 revenue rose 5.7% year over year, and the latest quarterly revenue level was the highest in the provided period.
• Margins are improving: Gross margin increased to approximately 41.2% from 39.6% in Q2 2025, while operating margin improved to about 14.0% from 13.1%.
• Latest-quarter earnings growth was strong: Common net income increased 15.4% year over year, and diluted EPS rose roughly 17% to $1.24.
• First-half cash generation improved: Based on the reported quarters, first-half 2026 operating cash flow was approximately $458 million versus $344 million in the comparable 2025 period, while estimated free cash flow increased to about $180 million from $80 million.
• Shareholder returns remain a priority: GE HealthCare repurchased $200 million of common stock and paid $16 million in dividends during Q2 2026. The average diluted share count also declined to 454 million from 458 million in Q2 2025.
• Liquidity is adequate but less cash-rich: Cash and equivalents stood at $2.11 billion in Q2 2026, down from $3.76 billion a year earlier, although the current ratio improved to approximately 1.26 from 1.16.
• Acquisition activity is affecting comparability: The company spent approximately $2.30 billion on acquisitions in Q1 2026, while Q2 acquisition spending was only $4 million. Investors should separate underlying operating trends from acquisition-related effects.
• Working capital remains a cash-flow headwind: Changes in operating assets and liabilities reduced Q2 2026 operating cash flow by $468 million, worsening from a $368 million use in Q2 2025.
• Debt remains substantial: Total short- and long-term debt was approximately $10.09 billion at Q2 2026, leaving the company with roughly $7.99 billion of net debt after cash. Interest expense was $114 million in the quarter.
• Goodwill and intangible assets create balance-sheet risk: Goodwill and intangible assets totaled approximately $16.99 billion in Q2 2026. A deterioration in acquired businesses could lead to impairment charges and pressure reported equity or earnings.

Overall, the latest quarter was encouraging for operating performance: GE HealthCare delivered faster profit growth than revenue growth and expanded margins. The main question for investors is whether this improvement can continue while the company converts earnings into cash, manages its acquisition-heavy balance sheet and gradually reduces leverage.